<DOC>
	<DOCNO>NCT00511784</DOCNO>
	<brief_summary>This study use PharMetrics MarketScan US health care insurance claim database estimate relative risk non-fatal venous thromboembolism ( include cerebral venous sinus thrombosis ) , ischemic stroke , acute myocardial infarction ( heart attack ) , current user ORTHO EVRA ( norelgestromin ethinyl estradiol contraceptive patch ) compare current user oral levonorgestrel-containing oral contraceptive 30 microgram ethinyl estradiol , special attention duration use .</brief_summary>
	<brief_title>Relative Risks Non-fatal Venous Thromboembolism , Ischemic Stroke Myocardial Infarction Users ORTHO EVRA ( Norelgestromin Ethinyl Estradiol Contraceptive Patch ) Compared Levonorgestrel-containing Oral Contraceptives .</brief_title>
	<detailed_description>This observational , retrospective study use PharMetrics MarketScan US health care claim insurance database ass occurrence venous thromboembolism ( include cerebral venous sinus thrombosis ) , ischemic stroke , acute myocardial infarction current user ORTHO EVRA ( norelgestromin ethinyl estradiol transdermal contraceptive patch ) compare current user levonorgestrel-containing oral contraceptive 30 microgram ethinyl estradiol , special attention duration use . PharMetrics United States base , ongoing longitudinal database information around 55 million covered life go back far 1995 . It make data contribute manage care plan throughout United States contain information pay claim pharmaceutical , medical diagnosis procedure well demographic information subject . There 3 set case reflect woman first-time record claim ICD-9 diagnosis follow study period : ( 1 ) deep vein thrombosis ( blood clot ) , pulmonary embolism , cerebral venous sinus thrombosis , venous thrombotic event ( VTE ) hospitalization , visit emergency room positive indication VTE diagnostic test result , time study period subsequent multiple claim anticoagulant treatment . The requirement multiple prescription anticoagulation therapy use provide evidence original diagnosis VTE confirm . ( 2 ) ischemic stroke hospitalize , ( 3 ) acute myocardial infarction ( heart attack ) acute coronary revascularization hospitalize . Three separate set control identified outcome . Planned analysis estimate relative risk idiopathic ( unknown cause ) ischemic stroke myocardial infarction , another analysis estimate relative risk idiopathic VTE . Conditional logistic regression use . Analyses stratify calendar year . The analysis repeat include non-idiopathic case VTE , ischemic stroke , acute myocardial infarction . Each transdermal patch contain 6 milligram norelgestromin 0.75 milligram ethinyl estradiol worn 1 week 3 consecutive week ; fourth week patch-free . Triphasic levonorgestrel-containing oral contraceptive 30 microgram ethinyl estradiol take 21 consecutive day follow pill inert pill 7 day . Duration use vary . NOTE : The study conduct two part . This study , CR014383 , represent first portion study . Study CR012022 , NCT00377988 , represent second portion extend study .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Users ORTHO EVRA first time user levonorgestrelcontaining oral contraceptive 30 microgram ethinyl estradiol April 1 , 2002 March 31 , 2006 , identify MarketScan PHARMetrics database use National Drug Code ( NDC ) assign FDA modify PharMetrics Start study contraceptive use April 1 , 2002 Six ( 6 ) month enrollment health plan prior event date match case At least four ( 4 ) month history claim record first record study drug dispensing . When woman receive levonorgestrelcontaining oral contraceptive 30 microgram ethinyl estradiol levonorgestrelcontaining oral contraceptive 20 microgram ethinyl estradiol , analysis include 30 microgram ethinyl estradiol preparation .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hormonal contraception</keyword>
	<keyword>Oral contraception</keyword>
	<keyword>Ethinyl estradiol , Levonorgestrel , Contraception</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Norelgestromin</keyword>
</DOC>